ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Gold Miners Bull 3X ETF

VanEck Vectors Junior Gold Miners ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Bank Of Montreal

Direxion Daily Technology Bull 3X ETF

VanEck Vectors Gold Miners ETF

Direxion Daily Financial Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

ProShares Ultra Bloomberg Natural Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

United States Natural Gas

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Financial Bear 3X Shar

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Juniper Networks Inc. Common Stock

Reddit Inc. Class A Common Stock

Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)

Carvana Co. Class A Common Stock

Whirlpool Corporation Common Stock

Oracle Corporation Common Stock

Alamos Gold Inc. Class A Common Shares

New Gold Inc.

Archer Aviation Inc. Class A Common Stock

Carnival Corporation Common Stock

ChargePoint Holdings Inc. Common Stock

WESCO International Inc. Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Leggett & Platt Incorporated Common Stock

Citigroup Inc. Common Stock

Quaker Houghton Common Stock

Dick's Sporting Goods Inc Common Stock

US Foods Holding Corp. Common Stock

Asbury Automotive Group Inc Common Stock

Olin Corporation Common Stock

Click here to get full coverage on Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease - TipRanks

Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease  TipRanks

Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease - TipRanks

Click here to get full coverage on Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage  FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Click here to get full coverage on How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com

How to Take Advantage of moves in (IMVT)  news.stocktradersdaily.com

How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com

Click here to get full coverage on IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm  PR Newswire

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire

Click here to get full coverage on Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?  Yahoo Finance

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Click here to get full coverage on Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role  Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Click here to get full coverage on Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints  Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Click here to get full coverage on Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win  Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Click here to get full coverage on Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer  Sjogren's Syndrome News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News

Click here to get full coverage on Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus  insights.citeline.com

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

Click here to get full coverage on Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission  BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Click here to get full coverage on Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep  Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Click here to get full coverage on Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop - Claim Depot

Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop  Claim Depot

Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop - Claim Depot

Click here to get full coverage on Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another  BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Click here to get full coverage on Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - AInvest

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?  AInvest

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - AInvest

Click here to get full coverage on Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs  Stock Titan

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan

Click here to get full coverage on IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - Yahoo Finance

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus  Yahoo Finance

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - Yahoo Finance

Click here to get full coverage on Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - Stock Titan

Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development  Stock Titan

Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - Stock Titan

Click here to get full coverage on Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses - Stock Titan

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses  Stock Titan

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses - Stock Titan

Click here to get full coverage on Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug  FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Click here to get full coverage on Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?  Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Click here to get full coverage on Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Pharmaceutical Technology

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses  Pharmaceutical Technology

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Pharmaceutical Technology

Click here to get full coverage on Immunovant Announces New CEO Amid Strategic Shift - TipRanks

Immunovant Announces New CEO Amid Strategic Shift  TipRanks

Immunovant Announces New CEO Amid Strategic Shift - TipRanks

Click here to get full coverage on Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?  Insider Monkey

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Click here to get full coverage on Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT)  Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Click here to get full coverage on SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)  PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

Click here to get full coverage on Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?  Insider Monkey

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey

Click here to get full coverage on Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Long Term Trading Analysis for (IMVT)  news.stocktradersdaily.com

Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Click here to get full coverage on Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?  Insider Monkey

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey

Click here to get full coverage on All change at Immunovant as Pete Salzmann retires - The Pharma Letter

All change at Immunovant as Pete Salzmann retires  The Pharma Letter

All change at Immunovant as Pete Salzmann retires - The Pharma Letter

Click here to get full coverage on Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently  Insider Monkey

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey

Click here to get full coverage on (IMVT) Investment Report - news.stocktradersdaily.com

(IMVT) Investment Report  news.stocktradersdaily.com

(IMVT) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)  Seeking Alpha

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha

Click here to get full coverage on Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win - Endpoints News

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win  Endpoints News

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win - Endpoints News

Click here to get full coverage on Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - TradingView

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025  TradingView

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - TradingView

Click here to get full coverage on Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts - Fierce Biotech

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts  Fierce Biotech

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts - Fierce Biotech

Click here to get full coverage on Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st

Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution  simplywall.st

Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st

Click here to get full coverage on Immunovant stock hits 52-week low at $19.04 amid market challenges - Investing.com

Immunovant stock hits 52-week low at $19.04 amid market challenges  Investing.com

Immunovant stock hits 52-week low at $19.04 amid market challenges - Investing.com

Click here to get full coverage on Immunovant stock price target cut to $35 at H.C. Wainwright - Investing.com

Immunovant stock price target cut to $35 at H.C. Wainwright  Investing.com

Immunovant stock price target cut to $35 at H.C. Wainwright - Investing.com

Click here to get full coverage on Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back? - RTTNews

Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back?  RTTNews

Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back? - RTTNews

Click here to get full coverage on Immunovant stock falls despite study success - Investing.com

Immunovant stock falls despite study success  Investing.com

Immunovant stock falls despite study success - Investing.com

Click here to get full coverage on Immunovant Announces Positive Phase 3 Study Results - TipRanks

Immunovant Announces Positive Phase 3 Study Results  TipRanks

Immunovant Announces Positive Phase 3 Study Results - TipRanks

Click here to get full coverage on Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires  Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Click here to get full coverage on Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter

Positive batoclimab data from Immunovant, but doubts raised on further development  The Pharma Letter

Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter

Click here to get full coverage on Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Immunovant Executives Sell Shares to Cover Tax Obligations  TradingView

Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Click here to get full coverage on Phase 3 trial of IMVT-1402 for MG advancing, with March as goal - Myasthenia Gravis News

Phase 3 trial of IMVT-1402 for MG advancing, with March as goal  Myasthenia Gravis News

Phase 3 trial of IMVT-1402 for MG advancing, with March as goal - Myasthenia Gravis News

Click here to get full coverage on Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence  MSN

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN

Click here to get full coverage on OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights  Business Wire

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on En garde, Vyvgart: Immunovant rolls out MG data - BioWorld MedTech

En garde, Vyvgart: Immunovant rolls out MG data  BioWorld MedTech

En garde, Vyvgart: Immunovant rolls out MG data - BioWorld MedTech

Click here to get full coverage on Top-line findings in Phase 3 batoclimab trial likely by late March - Myasthenia Gravis News

Top-line findings in Phase 3 batoclimab trial likely by late March  Myasthenia Gravis News

Top-line findings in Phase 3 batoclimab trial likely by late March - Myasthenia Gravis News

Click here to get full coverage on Why Immunovant Shares Are Taking a Hit - TipRanks

Why Immunovant Shares Are Taking a Hit  TipRanks

Why Immunovant Shares Are Taking a Hit - TipRanks

Click here to get full coverage on 10 Best Low Cost Stocks to Buy According to Billionaires - Insider Monkey

10 Best Low Cost Stocks to Buy According to Billionaires  Insider Monkey

10 Best Low Cost Stocks to Buy According to Billionaires - Insider Monkey

Click here to get full coverage on 11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

11 Stocks That Will Bounce Back According to Analysts  Insider Monkey

11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

Click here to get full coverage on Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data  Yahoo Finance

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. SEC 10-K Report - TradingView

Immunovant, Inc. SEC 10-K Report  TradingView

Immunovant Inc (IMVT)

Price Chart

Key Statistics

Technicals

About IMVT

Latest News

Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease - TipRanks

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com

Advanced Charts

Top Gainers

Top Losers